Depenni R, et al. - Via a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy of 297 patients with relapsing/metastatic head and neck cancer (RM HNC), the researchers intended to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab and to identify predictors of treatment response. Tumor site, residual tumor at the primary site and prior chemotherapy were noted as independent unfavorable predictors of objective response. Hence, to guide clinical practice and the design of future randomized clinical trials, the availability of new treatment modalities and epidemiological changes made the periodic reassessment of prognostic factors of great relevance.